Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT Concurrent Chemotherapy With Serplulimab in ES-SCLC
NCT05765825Phase 2Active, not recruiting
- Sponsor
- Sichuan University
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in small cell lung cancer (SCLC), sponsored by Sichuan University. Started Mar 2023; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05765825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765825.